Compare REZI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REZI | PTGX |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.4B |
| IPO Year | N/A | 2016 |
| Metric | REZI | PTGX |
|---|---|---|
| Price | $36.23 | $92.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $34.67 | ★ $88.33 |
| AVG Volume (30 Days) | ★ 1.8M | 904.2K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $7,435,000,000.00 | $209,217,000.00 |
| Revenue This Year | $12.39 | N/A |
| Revenue Next Year | $3.95 | $296.47 |
| P/E Ratio | ★ N/A | $128.06 |
| Revenue Growth | ★ 15.45 | N/A |
| 52 Week Low | $14.18 | $33.70 |
| 52 Week High | $45.29 | $93.25 |
| Indicator | REZI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 67.15 |
| Support Level | $33.30 | $88.30 |
| Resistance Level | $36.19 | $92.80 |
| Average True Range (ATR) | 1.44 | 2.79 |
| MACD | 0.73 | -0.03 |
| Stochastic Oscillator | 98.49 | 87.96 |
Resideo Technologies Inc is a manufacturer and developer of technology-driven products and components that provide critical comfort, energy management, and safety and security solutions. The company has two reportable segments; Products and Solutions segment offers temperature and humidity control, energy products and solutions, water and air solutions, smoke and carbon monoxide detection home safety products, security panels, sensors, peripherals, wire and cable, communications devices, video cameras, other home-related lifestyle convenience solutions; and ADI Global Distribution segment includes wholesale distributor of low-voltage security products including access control, fire detection, security, and video products. It derives majority of its revenue from the United States.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.